New scan agent could spot prostate cancer spread
NCT ID NCT07600554
First seen May 21, 2026 · Last updated May 24, 2026 · Updated 1 time
Summary
This early-phase study tests a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal is to check its safety and measure how much radiation the body receives during imaging. It may help doctors see where cancer has spread or returned.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
Bergamo, Bergamo, 24127, Italy
Contact
-
Ospedale San Raffaele S.r.l.
Milan, Milano, 20132, Italy
Contact
Conditions
Explore the condition pages connected to this study.